頭頸部がん治療の市場規模、シェア、動向分析レポート：治療タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年～2030年

頭頸部がん治療市場の成長と動向：

Grand View Researchの最新レポートによると、世界の頭頸部がん治療市場規模は2030年までに44億3,000万米ドルに達する見込みです。

同市場は2024～2030年にかけてCAGR 11.8％で成長すると予測されます。頭頸部がん（HNC）の診断と治療における進歩の増加は、費用対効果が高く、手術よりも標的が特定されるため、市場成長を促進すると予測されています。さまざまなタイプのHNCの有病率の増加と高齢者人口の増加が市場の主要促進要因です。

がん研究所によると、2021年には米国で約5万4,000人が異なるタイプのHNCと診断され、約1万1,000人が死亡したと報告されています。大量のアルコール摂取、長時間の日光暴露、エプスタイン・バー・ウイルス（EBV）などのがんを引き起こすウイルス感染、タバコの消費は、世界的に様々な頭頸部がんの発生率上昇に寄与している主要要因の一部です。

さらに、国連によると、2020年には全世界で60歳以上の高齢者が約7億2,700万人になると推定されています。また、高齢者人口は2020年の9.3％から2050年には16％に増加すると予想されています。加齢は免疫力を低下させ、さまざまな種類のHNCに罹患しやすくなるため、病気の治療のための治療の需要が増加します。

さらに、新規の標的薬や集学的治療アプローチの開発のための研究開発活動の増加は、頭頸部がんに罹患している患者の生存率の上昇につながると予想されます。例えば、Merck/DebiopharmのXevinapantは頭頸部扁平上皮がんの治療として現在第III相臨床試験中です。米国FDAから画期的治療の指定を受けています。

支援的な償還政策も市場成長の原動力になると予想されます。複数の団体が、患者やその介護者が医薬品を購入する際の資金援助を行っています。例えば、2022年7月に英国コロンビアがんは、カペシタビン、カルボプラチン、セツキシマブ、シスプラチン、ドセタキセル、ドキソルビシン、フルオロウラシル、ロイコボリンカルシウムを給付薬リストに含めました。こ一覧に含まれる薬剤は、承認された適応症に対する償還に適用されます。

頭頸部がん治療市場レポートハイライト

• 免疫療法が市場をリードし、2023年の世界収益シェアの60.07%を占め、予測期間中に最も速いCAGRで成長すると予測されます。
• 注射薬は2023年に市場をリードし、予測期間中のCAGRは12.0%で成長すると予測されます。注射剤は、全身療法において重要な役割を果たし、悪性腫瘍細胞と闘うための標的薬剤を送達します。
• 小売・専門薬局は、2023年の市場シェア57.67%で市場をリードし、予測期間中に最も速いCARで成長する見込みです。
• アジア太平洋の頭頸部がん治療市場は、頭頸部がんの有病率の増加、悪性腫瘍治療に対する意識の高まり、可処分所得の増加、医療改革の進展により、同市場で最も急速な成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブ概要

第3章 頭頸部がん治療市場の変数、動向、範囲

• 頭頸部がん治療市場の系統展望
  • 親市場展望
  • 補助市場
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• 頭頸部がん治療市場分析ツール
  • ポーターのファイブフォース分析
  • マクロ経済分析
• パイプライン分析
  • 臨床試験中の第3相パイプライン医薬品

第4章 頭頸部がん治療市場：治療タイプ別のビジネス分析

• 頭頸部がん治療市場：治療タイプの変動分析
• 治療タイプの変動分析と市場シェア、2023年と2030年
• 化学療法
• 免疫療法
• 標的療法

第5章 頭頸部がん治療市場：投与経路のビジネス分析

• 頭頸部がん治療市場：投与経路の変動分析
• 投与経路の変動分析と市場シェア、2023年と2030年
• 注射
• 経口

第6章 頭頸部がん治療市場：流通チャネルのビジネス分析

• 頭頸部がん治療市場：流通チャネルの変動分析
• 流通チャネルの変動分析と市場シェア、2023年と2030年
• 小売・専門薬局
• 病院薬局
• オンライン薬局

第7章 頭頸部がん治療市場：地域推定・動向分析、治療タイプ別、投与経路別、流通チャネル別

• 頭頸部がん治療市場：地域別展望
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2023年
  • Eli Lilly and Company
  • Sanofi
  • Merck &Co., Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company（BMS）
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 UK Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 23 UK Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 24 UK Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Australia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
• Table 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Head And neck cancer therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Therapy type and route of administration segment snapshot
• Fig. 11 Distribution channel segment snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Market dynamics
• Fig. 14 Porter's five forces analysis
• Fig. 15 PESTLE analysis
• Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
• Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
• Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
• Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
• Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
• Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
• Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
• Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
• Fig. 24 Global oral market, 2018 - 2030 (USD Million)
• Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
• Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
• Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
• Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
• Fig. 31 Regional marketplace: Key takeaways
• Fig. 32 Regional marketplace: Key takeaways
• Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Key country dynamics
• Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
• Fig. 37 Key country dynamics
• Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
• Fig. 40 Key country dynamics
• Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 45 Key country dynamics
• Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Oropharynx cancer incidence, 2020 - 2030
• Fig. 48 Germany insurance coverage
• Fig. 49 Key country dynamics
• Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 52 Key country dynamics
• Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 55 Key country dynamics
• Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Larynx cancer incidence, 2020 - 2030
• Fig. 58 Key country dynamics
• Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
• Fig. 61 Key country dynamics
• Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 64 Key country dynamics
• Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 71 Japan pharmaceutical registration
• Fig. 72 Key country dynamics
• Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
• Fig. 75 Regulatory details: China
• Fig. 76 Exclusivity formula
• Fig. 77 Key country dynamics
• Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 80 Registration details: India
• Fig. 81 Key country dynamics
• Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
• Fig. 84 Drug pricing: Australia
• Fig. 85 Contribution of PBS by disease
• Fig. 86 Key country dynamics
• Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
• Fig. 89 Key country dynamics
• Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
• Fig. 92 Reimbursement scenario: South Korea
• Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Larynx Cancer Incidence, 2020 to 2030
• Fig. 98 Regulatory framework
• Fig. 99 Reimbursement scenario
• Fig. 100 Key country dynamics
• Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
• Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Larynx cancer incidence, 2020 to 2030
• Fig. 105 Argentina pharmaceuticals registration details
• Fig. 106 Argentina pharmaceuticals reimbursement details
• Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Key country dynamics
• Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 112 Regulatory framework: South Africa
• Fig. 113 Regulatory framework: South Africa drug registration fees
• Fig. 114 Key country dynamics
• Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
• Fig. 117 Key country dynamics
• Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 120 Key country dynamics
• Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
• Fig. 123 Regulatory framework: Kuwait
• Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 125 Key company categorization
• Fig. 126 Company market share analysis, 2023
• Fig. 127 Strategic framework

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

• Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
• Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
• Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
• The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy Type
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Therapy Type and Route of Administration Segment Snapshot
• 2.3 Distribution Channel Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Head and Neck Cancer Therapeutics Market Variables, Trends, and Scope

• 3.1 Head and Neck Cancer Therapeutics Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increase in Prevalence of Head and Neck Cancers
    • 3.2.1.2 Rising Geriatric Population
    • 3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
    • 3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Paucity of Data Related to Safety and Efficacy
    • 3.2.2.2 High Cost of Treatment
• 3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Macroeconomic Analysis
• 3.4 Pipeline Analysis
  • 3.4.1 Phase 3 Pipeline drugs under clinical trails

Chapter 4 Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

• 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
• 4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
• 4.3 Chemotherapy
  • 4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.4 Immunotherapy
  • 4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5 Targeted Therapy
  • 4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5 Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

• 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
• 5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
• 5.3 Injectable
  • 5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.4 Oral
  • 5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6 Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

• 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
• 6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
• 6.3 Retail & Specialty Pharmacies
  • 6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4 Hospital Pharmacies
  • 6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5 Online Pharmacies
  • 6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7 Head and Neck Cancer Therapeutics Market: Regional Estimates and Trend Analysis, by Therapy Type, by Route of Administration, by Distribution Channel

• 7.1 Head and Neck Cancer Therapeutics Market: Regional Outlook
• 7.2 North America
  • 7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 Key Country Dynamics
    • 7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2.3 Target Disease: Cancer Incidence
    • 7.2.2.4 Market and Competitive Scenario
    • 7.2.2.5 Regulatory Framework
    • 7.2.2.6 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Key Country Dynamics
    • 7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3.3 Target Disease: Cancer Incidence
    • 7.2.3.4 Market and Competitive Scenario
    • 7.2.3.5 Regulatory Framework
    • 7.2.3.6 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 UK
    • 7.3.2.1 Key Country Dynamics
    • 7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.3 Target Disease Prevalence
    • 7.3.2.4 Market and Competitive Scenario
    • 7.3.2.5 Regulatory Framework
    • 7.3.2.6 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Key Country Dynamics
    • 7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3.3 Target Disease Prevalence
    • 7.3.3.4 Market and Competitive Scenario
    • 7.3.3.5 Regulatory Framework
    • 7.3.3.6 Reimbursement Scenario
  • 7.3.4 France
    • 7.3.4.1 Key Country Dynamics
    • 7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4.3 Target Disease Prevalence
    • 7.3.4.4 Market and Competitive Scenario
    • 7.3.4.5 Regulatory Framework
    • 7.3.4.6 Reimbursement Scenario
  • 7.3.5 Spain
    • 7.3.5.1 Key Country Dynamics
    • 7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5.3 Target Disease Prevalence
    • 7.3.5.4 Market and Competitive Scenario
    • 7.3.5.5 Regulatory Framework
    • 7.3.5.6 Reimbursement Scenario
  • 7.3.6 Italy
    • 7.3.6.1 Key Country Dynamics
    • 7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6.3 Target Disease Prevalence
    • 7.3.6.4 Market and Competitive Scenario
    • 7.3.6.5 Regulatory Framework
    • 7.3.6.6 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Key Country Dynamics
    • 7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7.3 Target Disease Prevalence
    • 7.3.7.4 Market and Competitive Scenario
    • 7.3.7.5 Regulatory Framework
    • 7.3.7.6 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Key Country Dynamics
    • 7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8.3 Target Disease Prevalence
    • 7.3.8.4 Market and Competitive Scenario
    • 7.3.8.5 Regulatory Framework
    • 7.3.8.6 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Key Country Dynamics
    • 7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9.3 Target Disease Prevalence
    • 7.3.9.4 Market and Competitive Scenario
    • 7.3.9.5 Regulatory Framework
    • 7.3.9.6 Reimbursement Scenario
  • 7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2.3 Target Disease Prevalence
    • 7.4.2.4 Market and Competitive Scenario
    • 7.4.2.5 Regulatory Framework
    • 7.4.2.6 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3.3 Target Disease Prevalence
    • 7.4.3.4 Market and Competitive Scenario
    • 7.4.3.5 Regulatory Framework
    • 7.4.3.6 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4.3 Target Disease Prevalence
    • 7.4.4.4 Market and Competitive Scenario
    • 7.4.4.5 Regulatory Framework
    • 7.4.4.6 Reimbursement Scenario
  • 7.4.5 Australia
    • 7.4.5.1 Key Country Dynamics
    • 7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5.3 Target Disease Prevalence
    • 7.4.5.4 Market and Competitive Scenario
    • 7.4.5.5 Regulatory Framework
    • 7.4.5.6 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Key Country Dynamics
    • 7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6.3 Target Disease Prevalence
    • 7.4.6.4 Market and Competitive Scenario
    • 7.4.6.5 Regulatory Framework
    • 7.4.6.6 Reimbursement Scenario
  • 7.4.7 South Korea
    • 7.4.7.1 Key Country Dynamics
    • 7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7.3 Target Disease Prevalence
    • 7.4.7.4 Market and Competitive Scenario
    • 7.4.7.5 Regulatory Framework
    • 7.4.7.6 Reimbursement Scenario
  • 7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5 Latin America
  • 7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2.3 Target Disease Prevalence
    • 7.5.2.4 Competitive Scenario
    • 7.5.2.5 Regulatory Framework
    • 7.5.2.6 Reimbursement Scenario
  • 7.5.3 Mexico
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3.3 Target Disease: Cancer Incidence
    • 7.5.3.4 Market and Competitive Scenario
    • 7.5.3.5 Regulatory Framework
    • 7.5.3.6 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Key Country Dynamics
    • 7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4.3 Target Disease Prevalence
    • 7.5.4.4 Competitive Scenario
    • 7.5.4.5 Regulatory Framework
    • 7.5.4.6 Reimbursement Scenario
  • 7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6 Middle East and Africa
  • 7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 Key Country Dynamics
    • 7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2.3 Target Disease Prevalence
    • 7.6.2.4 Competitive Scenario
    • 7.6.2.5 Regulatory Framework
    • 7.6.2.6 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Key Country Dynamics
    • 7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3.3 Target Disease Prevalence
    • 7.6.3.4 Competitive Scenario
    • 7.6.3.5 Regulatory Framework
    • 7.6.3.6 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 Key Country Dynamics
    • 7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4.3 Target Disease Prevalence
    • 7.6.4.4 Competitive Scenario
    • 7.6.4.5 Regulatory Framework
    • 7.6.4.6 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Key Country Dynamics
    • 7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5.3 Target Disease Prevalence
    • 7.6.5.4 Competitive Scenario
    • 7.6.5.5 Regulatory Framework
    • 7.6.5.6 Reimbursement Scenario
  • 7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

• 8.1 Recent Developments & Impact Analysis, By Key Market Participants
• 8.2 Company Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Eli Lilly and Company
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Sanofi
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.7. Cumberland Pharmaceuticals, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.8. Bristol-Myers Squibb Company (BMS)
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.9. AstraZeneca
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.10. Takeda Pharmaceutical Company Limited
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.11. Teva Pharmaceutical Industries Ltd.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.12. F. Hoffmann-La Roche Ltd
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives